Although SGLT2, typically expressed in the renal proximal tubule, has also been reported to play a critical role in the development of pancreatic or breast cancer [60, 61], our data showed that SGLT1, but not SGLT2, is upregulated in response to EGFR TKI treatment, which supports glucose uptake and cellular viability in NSCLC cells with acquired TKI resistance. The gene discussed is SLC5A1; the disease is breast carcinoma.